MDT

95.14

+0.13%↑

VEEV

293.44

+1.13%↑

142.17

+2.65%↑

HQY

91.48

-1%↓

TLRY

1.55

-1.9%↓

MDT

95.14

+0.13%↑

VEEV

293.44

+1.13%↑

142.17

+2.65%↑

HQY

91.48

-1%↓

TLRY

1.55

-1.9%↓

MDT

95.14

+0.13%↑

VEEV

293.44

+1.13%↑

142.17

+2.65%↑

HQY

91.48

-1%↓

TLRY

1.55

-1.9%↓

MDT

95.14

+0.13%↑

VEEV

293.44

+1.13%↑

142.17

+2.65%↑

HQY

91.48

-1%↓

TLRY

1.55

-1.9%↓

MDT

95.14

+0.13%↑

VEEV

293.44

+1.13%↑

142.17

+2.65%↑

HQY

91.48

-1%↓

TLRY

1.55

-1.9%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

15.16 0.07

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

15.01

Максимум

15.98

Ключови измерители
By Trading Economics
Приходи	13M -72M
Продажби	18M 38M
Марж на печалбата	-189.28
Служители	270
EBITDA	20M -64M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+126.06% upside

Дивиденти
By Dow Jones
Следващи печалби	4.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	416M 1.3B
Предишно отваряне	15.09
Предишно затваряне	15.16

Настроения в новините

By Acuity

34%

66%

106 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.10.2025 г., 23:25 ч. UTC

Значими двигатели на пазара

Salesforce Rises on New FY30 Financial Targets

15.10.2025 г., 18:52 ч. UTC

Печалби

Значими двигатели на пазара

Prologis Shares Gain on Raised Outlook, Data Center Growth

15.10.2025 г., 18:30 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software to Buy U.K.'s Tecvia Holding

15.10.2025 г., 17:19 ч. UTC

Придобивния, сливания и поглъщания

Drahi's Altice Rejects $20 Billion Joint Offer From Peers -- 2nd Update

15.10.2025 г., 17:11 ч. UTC

Придобивния, сливания и поглъщания

Anglo American, MMG Offer Concessions to EU Merger Watchdog in Nickel Deal Probe

15.10.2025 г., 23:48 ч. UTC

Пазарно говорене

Gold Steady, Supported by Expectations of Ongoing Central Bank Purchases -- Market Talk

15.10.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15.10.2025 г., 22:37 ч. UTC

Пазарно говорене

Economic Stars Are Aligning for RBA -- Market Talk

15.10.2025 г., 21:44 ч. UTC

Печалби

Stock Rally Is Lifting Wealth Managers. How Much Is Charles Schwab Benefiting? -- Barrons.com

15.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Financial Services Roundup: Market Talk

15.10.2025 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

Restaurant Brands Recommends Hldrs Do Not Tender Their Shrs to the Offer >QSR.T

15.10.2025 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

Restaurant Brands Notified of Unsolicited Mini-Tender Offer to Buy Shrs at $28.80/Shr

15.10.2025 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Restaurant Brands Notified of Unsolicited Mini-Tender Offer by NY Stk and Bond LLC to Purchase Up to 10,000 Common Shrs >QSR.T

15.10.2025 г., 20:34 ч. UTC

Печалби

Prologis Raises Outlook as Warehouse Leasing Picks Up -- WSJ

15.10.2025 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

RBI Recommends Hldrs Reject NYSB's "Mini-Tender Offer"

15.10.2025 г., 20:17 ч. UTC

Придобивния, сливания и поглъщания

GE Vernova Stock Feill With Latest Call to Sell -- Barrons.com

15.10.2025 г., 19:06 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Bank of America, Morgan Stanley, ASML, AMD, Nvidia, Bunge, Progressive, Abbott, and More -- Barrons.com

15.10.2025 г., 19:04 ч. UTC

Пазарно говорене

Oil Futures Post Back-to-Back Losses -- Market Talk

15.10.2025 г., 18:46 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

15.10.2025 г., 18:23 ч. UTC

Печалби

This Insurer Is the One of the Worst Stocks in the S&P 500 Today. Here's Why. -- Barrons.com

15.10.2025 г., 17:37 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software's Harris Operating Group Enters Into Agreement To Acquire TECVIA Holding GmbH >CSU.T

15.10.2025 г., 17:34 ч. UTC

Пазарно говорене

Oil Futures Lose Ground on Trade, Oversupply Concerns -- Market Talk

15.10.2025 г., 16:57 ч. UTC

Печалби

The Nation's Biggest Banks Are Saying the Economy Is Still Strong -- WSJ

15.10.2025 г., 16:51 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica Doesn't Disclose Financial Details

15.10.2025 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: RetinAI Partners With Pharmaceutical Companies, Research Organizations

15.10.2025 г., 16:49 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: Deal Reinforces the Group's Med-Tech Journey

15.10.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: Ikerian Specializes in Artificial Intelligence, Data Management in Eyecare

15.10.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: Ikerian Is a Health Technology Company, Operating Under the RetinAI Brand

15.10.2025 г., 16:47 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica Buys Ikerian

15.10.2025 г., 16:34 ч. UTC

Пазарно говорене

AMD Data Center Agreements Will Provide Big Revenue Growth -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

126.06% нагоре

12-месечна прогноза

Среден 34 USD 126.06%

Висок 56 USD

Нисък 17 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

106 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.